相似文献
1
Understanding COVID-19 in Africa.
Nat Rev Immunol. 2021 Aug;21(8):469-470. doi: 10.1038/s41577-021-00579-y. Epub 2021 Jun 24.
2
Balancing the Risks and Benefits of COVID-19 Vaccination for Pregnant Women and Their Children.
Front Immunol. 2021 Dec 16;12:748456. doi: 10.3389/fimmu.2021.748456. eCollection 2021.
3
COVID-19 vaccines: Keeping pace with SARS-CoV-2 variants.
Cell. 2021 Sep 30;184(20):5077-5081. doi: 10.1016/j.cell.2021.09.010. Epub 2021 Sep 17.
4
How severe are Omicron infections?
Nature. 2021 Dec;600(7890):577-578. doi: 10.1038/d41586-021-03794-8.
5
Lessons Relearned? H1N1, COVID-19, and Vaccination Planning.
J Public Health Manag Pract. 2021 Jan/Feb;27 Suppl 1, COVID-19 and Public Health: Looking Back, Moving Forward:S106-S110. doi: 10.1097/PHH.0000000000001289.
6
Covid-19 eradication: stopping transmission between countries.
BMJ. 2021 Jun 7;373:n1425. doi: 10.1136/bmj.n1425.
7
The indirect effect of mRNA-based COVID-19 vaccination on healthcare workers' unvaccinated household members.
Nat Commun. 2022 Mar 4;13(1):1162. doi: 10.1038/s41467-022-28825-4.
8
Core Concept: Herd immunity is an important-and often misunderstood-public health phenomenon.
Proc Natl Acad Sci U S A. 2021 May 25;118(21). doi: 10.1073/pnas.2107692118.
9
The long road.
Science. 2021 Feb 19;371(6531):768-772. doi: 10.1126/science.371.6531.768.
10
Will Omicron end the pandemic? Here's what experts say.
Nature. 2022 Feb;602(7895):20-21. doi: 10.1038/d41586-022-00210-7.
引用本文的文献
1
High seroprevalence of anti-SARS-CoV-2 antibodies in the capital of Chad.
J Public Health Afr. 2023 Jan 11;13(4):2255. doi: 10.4081/jphia.2022.2255. eCollection 2022 Dec 31.
2
Overcoming Vaccine Inequities and Research Gaps in Africa: Challenges and Opportunities Identified During the COVID-19 Pandemic.
Clin Infect Dis. 2025 Jul 22;80(Supplement_1):S9-S15. doi: 10.1093/cid/ciaf055.
3
Adults in Ghana generate higher and more durable neutralising antibody titres following primary course COVID-19 vaccination than matched UK adults: The HERITAGE Study.
BMC Med. 2025 May 28;23(1):312. doi: 10.1186/s12916-025-04157-0.
4
"Everything had stopped, no meeting, no gathering": Social interactions during the COVID-19 pandemic in the Central African Republic, the Democratic Republic of Congo, and Bangladesh.
PLoS One. 2025 May 27;20(5):e0323108. doi: 10.1371/journal.pone.0323108. eCollection 2025.
5
Seroprevalence and demographic characteristics of SARS-CoV-2-infected residents of Kibera informal settlement during the COVID-19 pandemic in Nairobi, Kenya: a cross-sectional study.
BMJ Open. 2025 Apr 2;15(4):e094546. doi: 10.1136/bmjopen-2024-094546.
6
Longitudinal humoral immunity against SARS-CoV-2 Spike following infection in individuals from Cameroon.
Virology. 2025 Apr;605:110467. doi: 10.1016/j.virol.2025.110467. Epub 2025 Feb 25.
7
Integrated Seroprevalence and Genome-Based Study of SARS-CoV-2 Viral Strains in N'Djamena: Insights Into Chad's COVID-19 Epicenter.
J Med Virol. 2025 Feb;97(2):e70234. doi: 10.1002/jmv.70234.
8
Pre-pandemic cross-reactive antibody and cellular responses against SARS-CoV-2 among female sex workers in Dakar, Senegal.
Front Public Health. 2025 Jan 23;13:1522733. doi: 10.3389/fpubh.2025.1522733. eCollection 2025.
9
Seroprevalence of SARS-CoV-2 and risk factors for infection among children in Uganda: A serial cross-sectional study.
PLoS One. 2024 Dec 23;19(12):e0312554. doi: 10.1371/journal.pone.0312554. eCollection 2024.
10
The impact of COVID-19 mitigation measures on neonatal health outcomes in sub-Saharan Africa: A systematic review and meta-analysis.
Public Health. 2025 Jan;238:108-116. doi: 10.1016/j.puhe.2024.11.022. Epub 2024 Dec 5.
本文引用的文献
1
Sero-surveillance for IgG to SARS-CoV-2 at antenatal care clinics in three Kenyan referral hospitals: Repeated cross-sectional surveys 2020-21.
PLoS One. 2022 Oct 14;17(10):e0265478. doi: 10.1371/journal.pone.0265478. eCollection 2022.
2
The first and second waves of the COVID-19 pandemic in Africa: a cross-sectional study.
Lancet. 2021 Apr 3;397(10281):1265-1275. doi: 10.1016/S0140-6736(21)00632-2. Epub 2021 Mar 24.
3
SARS-CoV-2 and common immunodominant regions may explain low COVID-19 incidence in the malaria-endemic belt.
New Microbes New Infect. 2020 Nov;38:100817. doi: 10.1016/j.nmni.2020.100817. Epub 2020 Nov 19.
4
Comorbidities and the COVID-19 pandemic dynamics in Africa.
Trop Med Int Health. 2021 Jan;26(1):2-13. doi: 10.1111/tmi.13504. Epub 2020 Oct 23.
5
Risk Factors for Coronavirus Disease 2019 (COVID-19) Death in a Population Cohort Study from the Western Cape Province, South Africa.
Clin Infect Dis. 2021 Oct 5;73(7):e2005-e2015. doi: 10.1093/cid/ciaa1198.
6
SeroTracker: a global SARS-CoV-2 seroprevalence dashboard.
Lancet Infect Dis. 2021 Apr;21(4):e75-e76. doi: 10.1016/S1473-3099(20)30631-9. Epub 2020 Aug 4.
7
Tuberculosis, COVID-19 and migrants: Preliminary analysis of deaths occurring in 69 patients from two cohorts.
Pulmonology. 2020 Jul-Aug;26(4):233-240. doi: 10.1016/j.pulmoe.2020.05.002. Epub 2020 May 14.
Zotero 插件